Abstract: The invention provides a gel patch comprising a support and an adhesive layer on the support, wherein the adhesive layer comprises 1.5 to 2.5 mass % of ketoprofen, 1.5 to 2.5 mass % of 4-tert-butyl-4?-methoxydibenzoylmethane and 12 to 18 mass % of propylene glycol, based on the total mass of the adhesive layer.

Abstract: The invention provides a gel patch comprising a support and an adhesive layer on the support, wherein the adhesive layer comprises 1.5 to 2.5 mass % of ketoprofen, 1.5 to 2.5 mass % of 4-tert-butyl-4?-methoxydibenzoylmethane and 12 to 18 mass % of propylene glycol, based on the total mass of the adhesive layer.

Abstract: A patch comprising a support layer and an adhesive layer, wherein the adhesive layer comprises diclofenac sodium, dimethyl sulfoxide, and citric acid; a mass ratio between the diclofenac sodium and the citric acid (mass of diclofenac sodium:mass of citric acid) is 1:0.15 to 1:0.45; and a mass ratio between the diclofenac sodium and the dimethyl sulfoxide (mass of diclofenac sodium:mass of dimethyl sulfoxide) is 1:0.75 to 1:3.

Abstract: A patch comprising a support layer and an adhesive layer, wherein the adhesive layer comprises diclofenac sodium, dimethyl sulfoxide, and citric acid; a mass ratio between the diclofenac sodium and the citric acid (mass of diclofenac sodium:mass of citric acid) is 1:0.15 to 1:0.45; and a mass ratio between the diclofenac sodium and the dimethyl sulfoxide (mass of diclofenac sodium:mass of dimethyl sulfoxide) is 1:0.75 to 1:3.

Abstract: The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.

Abstract: A method for producing a patch having a high skin penetrability and a high pharmaceutical physical properties such as adhesion and cohesiveness, and a long-term storability. The patch is produced by first obtaining an adhesive agent layer composition containing oxybutynin and/or salt thereof as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, an organic acid, and a tackifier; heating the adhesive agent layer composition at a temperature in a range from a melting point of the drug to a temperature higher than the melting point by 10° C. for 2 to 24 hours; and slowly cooling the heated adhesive agent layer composition to obtain the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.

Abstract: A method for producing a patch having a high skin penetrability and a high pharmaceutical physical properties such as adhesion and cohesiveness, and a long-term storability. The patch is produced by first obtaining an adhesive agent layer composition containing oxybutynin and/or salt thereof as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, an organic acid, and a tackifier; heating the adhesive agent layer composition at a temperature in a range from a melting point of the drug to a temperature higher than the melting point by 10° C. for 2 to 24 hours; and slowly cooling the heated adhesive agent layer composition to obtain the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.

Abstract: Provided is a microneedle device where a coating agent has been applied to microneedles having a biodegradable resin. It has been found that the application of the coating agent to microneedles of a biodegradable resin having a predetermined strength allows the microneedles to have excellent performance. Further, with regard to the coating agent, a predetermined type and amount thereof are also useful to demonstrate performance. Accordingly, when a microneedle device 1 is arranged so that at least a part of a microneedle array 2 provided with microneedles 3 made from polylactic acid having a weight average molecular weight of 40,000 or more is coated with a carrier containing physiologically active ingredients, it is possible to attain excellent migration characteristics of the physiologically active ingredients to a living body.

Abstract: Relations between crystallinity and performance of a biodegradable resin, between weight-average molecular weight and strength thereof, and between weight-average molecular weight and performance thereof were clarified. As a result thereof, when a microneedle array was provided with microneedles containing noncrystalline polylactic acid which had a weight-average molecular weight of 40,000 to 100,000, it was possible to obtain a microneedle array which could maintain its functional performance.

Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.

Abstract: Relations between crystallinity and performance of a biodegradable resin, between weight-average molecular weight and strength thereof, and between weight-average molecular weight and performance thereof were clarified. As a result thereof, when a microneedle array was provided with microneedles containing noncrystalline polylactic acid which had a weight-average molecular weight of 40,000 to 100,000, it was possible to obtain a microneedle array which could maintain its functional performance.

Abstract: Provided is a microneedle device where a coating agent has been applied to microneedles having a biodegradable resin. It has been found that the application of the coating agent to microneedles of a biodegradable resin having a predetermined strength allows the microneedles to have excellent performance. Further, with regard to the coating agent, a predetermined type and amount thereof are also useful to demonstrate performance. Accordingly, when a microneedle device 1 is arranged so that at least a part of a microneedle array 2 provided with microneedles 3 made from polylactic acid having a weight average molecular weight of 40,000 or more is coated with a carrier containing physiologically active ingredients, it is possible to attain excellent migration characteristics of the physiologically active ingredients to a living body.

Abstract: A patch agent of the present invention comprises a support, and an adhesive layer laid on the support and containing an adhesive base and a drug, wherein the adhesive base contains an acrylic polymer substantially having no carboxyl and no hydroxyl in molecules thereof, and a rubber-based polymer, so as to achieve sufficiently high skin permeability of the drug and preparation properties. Accordingly, the present invention enables administration of the drug through skin to be implemented with drug administration effect at a sufficiently high level and on a stable basis.

Abstract: The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.

Abstract: A cover material adapted to cover the entirety of a patch is provided. The cover material has a support layer and, superimposed on a surface thereof, a pressure sensitive adhesive layer. The patch has a support film with a thickness of 12- to 30 ?m and, superimposed thereon, a drug containing layer. The cover material may be attached to the surface of the support film and to the skin around the patch so that the pressure sensitive adhesive layer is brought into contact with edges of the drug containing layer. Additionally, the pressure sensitive adhesive layer contains an adhesive resulting from the polymerization of vinyl acetate or N-vinyl-2-pyrrolidone and a C8 alkyl (meth)acrylate as essential monomers. Thus, there is provided a cover material that, when a patch medicated with, for example, mesylic acid pergolide is fixed on diseased part, such as, a part of the skin, by covering the patch, is capable of reducing irritation, etc. on the diseased part.

Abstract: Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is contained in an amount of 9 to 50% by mass relative to the total weight of the adhesive. The preparation (particularly, one having a non-aqueous adhesive layer) shows an excellent penetration of donepezil and/or a salt thereof into the skin, retains good stability of the active ingredient therein, and is remarkably reduced in local stimulation and adverse side effects.

Abstract: It is intended to provide pergolide-containing transdermal preparations having reduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.

Abstract: It is intended to provide a transdermal absorption patch which is highly excellent in transdermal absorption properties and long-lasting drug effect even in the case where a drug-effect component contained in the transdermal absorption patch is a basic drug hardly soluble in a pressure-sensitive adhesive base, has a high stability of the drug contained therein with the passage of time and can achieve improvement in the compliance and simplification of the administration method. These problems can be solved by providing a transdermal absorption patch which contains a basic drug having an octanol/water partition coefficient (logarithm) in the free state of 3 or above, a pressure-sensitive adhesive base and a (meth)acrylic copolymer having carboxyl group.

Abstract: The patch preparation of the present invention is a patch preparation comprising a backing and an adhesive layer provided on the backing; wherein, the adhesive layer contains (A) a volatile organic acid and (B) a basic drug; the molar concentration ratio [(MA)/(MB)] between the molar concentration (MA) of the component (A) and the molar concentration (MB) of the component (B) in the adhesive layer is 0.5 or more; and the component (B) contains a basic drug formed as an ion pair with an anion component.

Abstract: The present invention provides a cover material 10, adapted to be attached to skin in a manner covering over the entirety of a patch 20, comprising a pressure-sensitive adhesive layer 12 on one side of a support 11, wherein said patch 20 comprises a drug-containing layer 22 for contacting with the skin, said layer being provided on a support film 21 with a thickness of 12-30 ?m, and wherein the cover material 10 is adapted to be attached to said support film 21 and a region of the skin around said patch 20 in such a manner that the pressure-sensitive adhesive layer 12 contacts with the edges of the drug-containing layer 22, and the pressure-sensitive adhesive layer 12 comprises a pressure-sensitive adhesive obtained by polymerizing vinyl acetate or N-vinyl-2-pyrrolidone and a (meth)acrylic acid alkyl ester with a C8 alkyl group as essential monomer components.